drugset / Trial / NCT00422175

Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312

NCT00422175

Phase 1 Completed 63 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and effect of oral BAF312 on bodily functions as well as the body's absorption, distribution, metabolism, and excretion of BAF312 in healthy volunteers

Timeline

Start
2006-10
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BAF312 Unknown Oral

Indications

No indication recorded.